Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986001 in Treatment-Naive HIV-1 Infection
NCT01489046Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2011
- Primary completion
- Mar 2013
- Countries
- 13
01
Overview
A Phase 2 trial of censavudine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Bristol Myers Squibb. Started Feb 2011; status: terminated.
02
Drugs
censavudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01489046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01489046.